BackOrganogenesis Holdings Overview

Organogenesis Holdings EBIT

Latest ebit for ORGO: $-87M, below the Healthcare sector average of $1.9T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$29.49M
↓ 242.27% YoY

As of Sep 30, 2026

Annual EBIT (TTM)

-$86.52M
↓ 929.67% YoY

Trailing 12 months ending Sep 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Organogenesis Holdings (ORGO) FAQ

The latest EBIT for ORGO is $-87M as of September 2026. That compares with $-8.4M in the prior-year period — down 929.7% year over year. That is below the Healthcare sector average of $1.9T. Investors often review this figure alongside Organogenesis Holdings's historical trend and sector peers before judging valuation or financial health.

Over the past year, ORGO's EBIT moved from $-8.4M to $-87M — a 929.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Organogenesis Holdings's operating scale or balance-sheet position.

Against Healthcare companies, ORGO currently prints $-87M for EBIT, while the sector average sits near $1.9T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Organogenesis Holdings's growth, margins, and balance sheet.

A EBIT figure of $-87M for ORGO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.9T. Explore the charts below for those layers of context.

After noting ORGO's EBIT ($-87M), review year-over-year change from $-8.4M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.